Journal Mobile Options
Table of Contents
Vol. 69, No. 2, 2010
Issue release date: March 2010
Section title: Short Communication
Gynecol Obstet Invest 2010;69:128–130
(DOI:10.1159/000263460)

Can Prenatal Screening for Fetal Alcohol Spectrum Disorder Be Justified? A Commentary

Mizejewski G.J.
Division of Translational Medicine, Wadsworth Center, New York State Department of Health, Albany, N.Y., USA

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger (new!)
  • Unrestricted printing, no saving restrictions for personal use
  • Reduced rates with a PPV account
read more

Direct: USD 33.00
Account: USD 23.00

Select

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Automatic perpetual access to all articles of the subscribed year(s)
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select


Article / Publication Details

First-Page Preview
Abstract of Short Communication

Received: 6/17/2009
Accepted: 10/12/2009
Published online: 12/4/2009

Number of Print Pages: 3
Number of Figures: 0
Number of Tables: 0

ISSN: 0378-7346 (Print)
eISSN: 1423-002X (Online)

For additional information: http://www.karger.com/GOI

Abstract

Fetal alcohol spectrum disorder (FASD) is the leading cause of non-genetic mental retardation in the USA, possibly exceeding even Down syndrome, which is currently approaching 1 in 500 live births. Alcohol consumption during pregnancy results in brain, craniofacial and heart defects, neurotoxicity, and immune dysfunction. The preferred action taken to prevent alcohol consumption during pregnancy is abstinence. However, the detection, diagnosis, and treatment of FASD remain a major public health need in this country and throughout the world. The biochemical molecules involved in the developmental anomalities encompass a vast array of signal transduction and synaptic pathways which involve neurotransmitters and neurotrophic peptides. Recent advances in medicine-based therapies for FASD have been reported, and include the use of small molecule agonists, antagonists, and competitive inhibitors. Since biomarkers for FASD have previously been identified in clinical research reports, multicenter screening feasibility studies now seem warranted and could be initiated following adequate funding, protocols, procedures, and institutional review board approvals.


  

Author Contacts

G.J. Mizejewski, PhD
Division of Translational Medicine, Wadsworth Center
New York State Department of Health
Empire State Plaza, Albany, NY 12201 (USA)
Tel. +1 518 486 5900, Fax +1 518 402 5002, E-Mail mizejew@wadsworth.org

  

Article Information

Received: June 17, 2009
Accepted after revision: October 12, 2009
Published online: December 4, 2009
Number of Print Pages : 3
Number of Figures : 0, Number of Tables : 0, Number of References : 20

  

Publication Details

Gynecologic and Obstetric Investigation

Vol. 69, No. 2, Year 2010 (Cover Date: March 2010)

Journal Editor: D'Hooghe T. (Leuven)
ISSN: 0378-7346 (Print), eISSN: 1423-002X (Online)

For additional information: http://www.karger.com/GOI


Article / Publication Details

First-Page Preview
Abstract of Short Communication

Received: 6/17/2009
Accepted: 10/12/2009
Published online: 12/4/2009

Number of Print Pages: 3
Number of Figures: 0
Number of Tables: 0

ISSN: 0378-7346 (Print)
eISSN: 1423-002X (Online)

For additional information: http://www.karger.com/GOI


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.